Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
EYPT EyePoint Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: EYPT
Price (delayed)
$9.64
Market cap
$663.35M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.42
Enterprise value
$600.35M
EYP-1901 is a potential twice-yearly sustained delivery intravitreal anti-VEGF treatment for wet age-related macular degeneration. EYP-1901 leverages a bioerodible formulation of EyePoint's proprietary Durasert® sustained release technology with vorolanib, a
Highlights
EYPT's quick ratio has surged by 58% year-on-year
EYPT's gross profit is up by 32% since the previous quarter and by 15% year-on-year
EYPT's equity is up by 19% year-on-year but it is down by 11% since the previous quarter
The net income has dropped by 86% year-on-year and by 12% since the previous quarter
The EPS has contracted by 34% YoY and by 4.3% from the previous quarter
Key stats
What are the main financial stats of EYPT
Market
Valuations
Earnings
Shares outstanding
68.81M
Market cap
$663.35M
Enterprise value
$600.35M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.22
Price to sales (P/S)
12
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.71
Revenue
$56.04M
Gross profit
$52.28M
Operating income
-$161.37M
Net income
-$146.78M
EBIT
-$146.68M
EBITDA
-$144.94M
Free cash flow
-$151.31M
Per share
Balance sheet
Liquidity
EPS
-$2.42
EPS diluted
-$2.42
Free cash flow per share
-$2.17
Book value per share
$4.34
Revenue per share
$0.8
TBVPS
$5.2
Total assets
$362.56M
Total liabilities
$64.17M
Debt
$22.31M
Equity
$298.4M
Working capital
$285.31M
Debt to equity
0.07
Current ratio
7.85
Quick ratio
7.65
Net debt/EBITDA
0.43
Margins
Efficiency
Dividend
EBITDA margin
-258.6%
Gross margin
93.3%
Net margin
-261.9%
Operating margin
-287.9%
Return on assets
-41.8%
Return on equity
-54.3%
Return on invested capital
-62.6%
Return on capital employed
-45.7%
Return on sales
-261.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
EYPT stock price
How has the EyePoint Pharmaceuticals stock price performed over time
Intraday
-7.04%
1 week
14.49%
1 month
61.74%
1 year
10.17%
YTD
29.4%
QTD
77.86%
Financial performance
How have EyePoint Pharmaceuticals's revenue and profit performed over time
Revenue
$56.04M
Gross profit
$52.28M
Operating income
-$161.37M
Net income
-$146.78M
Gross margin
93.3%
Net margin
-261.9%
The operating income has plunged by 86% YoY and by 11% from the previous quarter
The net income has dropped by 86% year-on-year and by 12% since the previous quarter
The company's operating margin has shrunk by 66% YoY but it rose by 15% QoQ
The net margin has dropped by 66% year-on-year but it has increased by 13% since the previous quarter
Price vs fundamentals
How does EYPT's price correlate with its fundamentals
Growth
What is EyePoint Pharmaceuticals's growth rate over time
Valuation
What is EyePoint Pharmaceuticals stock price valuation
P/E
N/A
P/B
2.22
P/S
12
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.71
The EPS has contracted by 34% YoY and by 4.3% from the previous quarter
The stock's price to book (P/B) is 43% less than its 5-year quarterly average of 3.9 but 31% more than its last 4 quarters average of 1.7
EYPT's equity is up by 19% year-on-year but it is down by 11% since the previous quarter
EYPT's P/S is 45% above its 5-year quarterly average of 8.3 and 36% above its last 4 quarters average of 8.8
The revenue has increased by 30% since the previous quarter and by 12% year-on-year
Efficiency
How efficient is EyePoint Pharmaceuticals business performance
The ROS has plunged by 67% YoY but it has grown by 13% from the previous quarter
EYPT's return on assets is down by 35% year-on-year and by 10% since the previous quarter
The ROIC is up by 19% QoQ
EyePoint Pharmaceuticals's ROE has decreased by 9% YoY and by 7% from the previous quarter
Dividends
What is EYPT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for EYPT.
Financial health
How did EyePoint Pharmaceuticals financials performed over time
EYPT's quick ratio has surged by 58% year-on-year
EyePoint Pharmaceuticals's current ratio has soared by 55% YoY
The debt is 93% smaller than the equity
EYPT's equity is up by 19% year-on-year but it is down by 11% since the previous quarter
EYPT's debt to equity is up by 17% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.